Anktiva
Definition
Anktiva (nogapendekin alfa inbakicept-pmln) is a brand name for a first-in-class interleukin-15 (IL-15) receptor agonist immunotherapy approved by the FDA.
It is used in combination with bacillus Calmette-Guérin (BCG) to treat adults with BCG-unresponsive non-muscle invasive bladder cancer (NMIBC) with carcinoma in situ (CIS).
Anktiva activates natural killer (NK) cells and enhances T-cell stimulation, boosting the body's innate immune response against cancer cells.
Examples
The urologist prescribed Anktiva, giving the patient's immune system the upgrade it needed to outmaneuver sneaky bladder cancer cells.
With Anktiva teaming up with BCG, Bob joked that his bladder was hosting an exclusive immune cell party where cancer wasn't invited.
Doctors hailed Anktiva as the new sheriff in town for NMIBC, rallying NK cells like a boss-level power-up in a video game.
After starting Anktiva, the patient quipped that his body had finally hired a hit squad specialized in targeting rogue cells.